User login
Key clinical point: A Japanese real-world study found no overall survival (OS) benefit with adjuvant tegafur-uracil (UFT) chemotherapy compared with no chemotherapy in patients with completely resected stage I non–small-cell lung cancer (NSCLC).
Major finding: There was no significant difference in OS between the UFT and no chemotherapy groups (multivariate analysis: P = .3285; univariate analysis: P = .7554), with the exception of a subgroup with a tumor size of >3 cm and without ground-glass attenuation who benefitted from UFT (univariate analysis: hazard ratio 0.71; log-rank P = .0414).
Study details: In a real-world observational cohort study, patients treated with adjuvant UFT (n = 1549) were compared with those treated without any adjuvant chemotherapy (n = 3338).
Disclosures: The study was funded by Taiho Pharmaceutical. The authors reported ties with one or more pharmaceutical companies, including Taiho.
Source: Shukuya T et al. Efficacy of adjuvant chemotherapy with tegafur/uracil in patients with completely resected, node-negative non-small cell lung cancer – real-world data in the era of molecularly targeted agents and immunotherapy. JTO Clin Res Rep. 2022 (Apr 6). Doi: 10.1016/j.jtocrr.2022.100320
Key clinical point: A Japanese real-world study found no overall survival (OS) benefit with adjuvant tegafur-uracil (UFT) chemotherapy compared with no chemotherapy in patients with completely resected stage I non–small-cell lung cancer (NSCLC).
Major finding: There was no significant difference in OS between the UFT and no chemotherapy groups (multivariate analysis: P = .3285; univariate analysis: P = .7554), with the exception of a subgroup with a tumor size of >3 cm and without ground-glass attenuation who benefitted from UFT (univariate analysis: hazard ratio 0.71; log-rank P = .0414).
Study details: In a real-world observational cohort study, patients treated with adjuvant UFT (n = 1549) were compared with those treated without any adjuvant chemotherapy (n = 3338).
Disclosures: The study was funded by Taiho Pharmaceutical. The authors reported ties with one or more pharmaceutical companies, including Taiho.
Source: Shukuya T et al. Efficacy of adjuvant chemotherapy with tegafur/uracil in patients with completely resected, node-negative non-small cell lung cancer – real-world data in the era of molecularly targeted agents and immunotherapy. JTO Clin Res Rep. 2022 (Apr 6). Doi: 10.1016/j.jtocrr.2022.100320
Key clinical point: A Japanese real-world study found no overall survival (OS) benefit with adjuvant tegafur-uracil (UFT) chemotherapy compared with no chemotherapy in patients with completely resected stage I non–small-cell lung cancer (NSCLC).
Major finding: There was no significant difference in OS between the UFT and no chemotherapy groups (multivariate analysis: P = .3285; univariate analysis: P = .7554), with the exception of a subgroup with a tumor size of >3 cm and without ground-glass attenuation who benefitted from UFT (univariate analysis: hazard ratio 0.71; log-rank P = .0414).
Study details: In a real-world observational cohort study, patients treated with adjuvant UFT (n = 1549) were compared with those treated without any adjuvant chemotherapy (n = 3338).
Disclosures: The study was funded by Taiho Pharmaceutical. The authors reported ties with one or more pharmaceutical companies, including Taiho.
Source: Shukuya T et al. Efficacy of adjuvant chemotherapy with tegafur/uracil in patients with completely resected, node-negative non-small cell lung cancer – real-world data in the era of molecularly targeted agents and immunotherapy. JTO Clin Res Rep. 2022 (Apr 6). Doi: 10.1016/j.jtocrr.2022.100320